Alzheimer's Disease THErapy With NEuroaid II

Summary

ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.

Timeline

Start

2026-08

Primary completion

2029-02

Completion

2029-05

Publications

• Background Dib M, Ampil E, Kee HF, et al. A review of NeuroAiD™ II (MLC901) development in Alzheimer's disease treatment: promises of a multimodal pathway. J Neurol Res Rev Rep. 2022 Jun 30;1-13.
• Background Lee WT, Hsian CCL, Lim YA. The effects of MLC901 on tau phosphorylation. Neuroreport. 2017 Nov 8;28(16):1043-1048. doi: 10.1097/WNR.0000000000000884.
• Background Lim YA, Murray LA, Lai MK, Chen C. NeuroAiD(R) (MLC601) and amyloid precursor protein processing. Cerebrovasc Dis. 2013;35 Suppl 1:30-7. doi: 10.1159/000346236. Epub 2013 Mar 14.
• Background Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, Veyssiere J, Onteniente B, Lazdunski M. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013;35 Suppl 1:1-7. doi: 10.1159/000346228. Epub 2013 Mar 14.
• Background Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, Onteniente B, Lazdunski M. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010 Jun;58(7):987-1001. doi: 10.1016/j.neuropharm.2010.01.001. Epub 2010 Jan 11.

Drugs

Indications